
To determine the zzso dose zzso and the zzso zzso zzso of the zzso plus zzso combination regimen, to explore its safety and zzso and to assess its zzso activity in patients with advanced solid zzso 

Forty-eight patients received the combination of zzso plus zzso zzso was administered as a 15-minute infusion followed by zzso as a zzso infusion 1 hour later, repeated every 3 zzso Seven dose levels were zzso ranging from 2 to zzso zzso and from 85 to 130 zzso for zzso and zzso zzso The zzso of both zzso and zzso was assessed at the last three dose zzso 

zzso patients were zzso for zzso Severe zzso usually occurred from dose level V zzso 3 zzso and zzso 130 zzso This combination was not zzso zzso only sporadic grades 3 and 4 zzso and/or zzso without zzso There was no zzso zzso were zzso and zzso despite systematic zzso zzso zzso level VI zzso zzso zzso and zzso 130 zzso was deemed to be the zzso Eight confirmed partial responses were zzso six patients with zzso zzso (both zzso and zzso one with zzso pancreatic zzso and one with zzso zzso zzso of the zzso of both drugs did not suggest any drug zzso 

The combination of zzso and zzso given as consecutive short infusions every 3 weeks seems to be an acceptable regimen that allows a zzso as high as the sum of the recommended doses of each agent given zzso The dose recommended for further phase II studies is zzso 3 zzso and zzso 130 zzso every 3 zzso Promising zzso activity has been observed in patients with zzso zzso 

